Iron Overload and Breast Cancer: Iron Chelation as a Potential Therapeutic Approach
Abstract
:1. Introduction
1.1. Importance of Iron in Human Health
1.2. Iron Overload and Its Implication on Breast Cancer
1.3. Breast Cancer and Organotrophic Metastasis
1.4. Global Trends in Breast Cancer Rates
1.5. General and Targeted Therapies of Breast Cancer
- Inhibitors Targeting Protein Kinase B (Akt)/Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Pathway
- Cyclin-Dependent Kinases 4 and 6 Inhibitors (CDK 4/6 Inhibitors)
- Poly (ADP ribose) Polymerase (PARP) Inhibitors
- Tyrosine Kinase Inhibitors
- Vascular Endothelial Growth Factor-A Inhibitors
2. A Summary of a Search of Literatures/Records
3. Iron Chelation in Treating Cancers
4. Dual Roles of Iron in Cancer
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
References
- Ganz, T.; Nemeth, E. Iron homeostasis in host defence and inflammation. Nat. Rev. Immunol. 2015, 15, 500–510. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jiang, Y.; Li, C.; Wu, Q.; An, P.; Huang, L.; Wang, J.; Chen, C.; Chen, X.; Zhang, F.; Ma, L.; et al. Iron-dependent histone 3 lysine 9 demethylation controls B cell proliferation and humoral immune responses. Nat. Commun. 2019, 10, 1–15. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wallace, D.F. Regulation of Folate Homeostasis. In Montreal, Canada, 15–20 June 1986; De Gruyter: Berlin, Germany; Boston, MA, USA, 2019; Volume 37, pp. 925–928. [Google Scholar] [CrossRef]
- Saha, P.; Yeoh, B.S.; Xiao, X.; Golonka, R.M.; Kumarasamy, S.; Vijay-Kumar, M. Enterobactin, an iron chelating bacterial siderophore, arrests cancer cell proliferation. Biochem. Pharmacol. 2019, 168, 71–81. [Google Scholar] [CrossRef] [PubMed]
- Abbaspour, N.; Hurrell, R.; Kelishadi, R. Review on iron and its importance for human health. J. Res. Med. Sci. 2014, 19, 164–174. [Google Scholar] [PubMed]
- Knutson, M.D. Iron transport proteins: Gateways of cellular and systemic iron homeostasis. J. Biol. Chem. 2017, 292, 12735–12743. [Google Scholar] [CrossRef] [Green Version]
- Lamy, P.J.; Durigova, A.; Jacot, W. Iron homeostasis and anemia markers in early breast cancer iron and breast cancer. Clin. Chim. Acta 2014, 434, 34–40. [Google Scholar] [CrossRef]
- Walker, J.; Walker, S.M. Review: Effects of iron overload on the immune system. Ann. Clin. Lab. Sci. 2000, 30, 354–365. [Google Scholar]
- Hatcher, H.C.; Singh, R.N.; Torti, F.M.; Torti, S.V. Synthetic and natural iron chelators: Therapeutic potential and clinical use. Futur. Med. Chem. 2009, 1, 1643–1670. [Google Scholar] [CrossRef] [Green Version]
- Tang, D.; Kang, R.; Coyne, C.B.; Zeh, H.J.; Lotze, M.T. PAMPs and DAMPs: Signal 0s that spur autophagy and immunity. Immunol. Rev. 2012, 249, 158–175. [Google Scholar] [CrossRef]
- Lehmann, C.; Islam, S.; Jarosch, S.; Zhou, J.; Hoskin, D.; Greenshields, A.; Al-Banna, N.; Sharawy, N.; Sczcesniak, A.; Kelly, M.; et al. The Utility of Iron Chelators in the Management of Inflammatory Disorders. Mediat. Inflamm. 2015, 2015, 516740. [Google Scholar] [CrossRef] [Green Version]
- Yu, Y.; Gutierrez, E.; Kovacevic, Z.; Saletta, F.; Obeidy, P.; Rahmanto, Y.S.; Richardson, D.R. Iron Chelators for the Treatment of Cancer. Curr. Med. Chem. 2012, 19, 2689–2702. [Google Scholar] [CrossRef] [PubMed]
- Rouault, T.A.; Tong, W.H. Iron–sulfur cluster biogenesis and human disease. Trends Genet. 2008, 24, 398–407. [Google Scholar] [CrossRef] [Green Version]
- Ward, D.M.; Cloonan, S.M. Mitochondrial Iron in Human Health and Disease. Annu. Rev. Physiol. 2019, 81, 453–482. [Google Scholar] [CrossRef]
- Menshawey, R.; Menshawey, E.; Alserr, A.H.K.; Abdelmassih, A.F. Low iron mitigates viral survival: Insights from evolution, genetics, and pandemics—a review of current hypothesis. Egypt. J. Med Hum. Genet. 2020, 21, 75. [Google Scholar] [CrossRef]
- Hershko, C. Iron loading and its clinical implications. Am. J. Hematol. 2007, 82 (Suppl. S12), 1147–1148. [Google Scholar] [CrossRef] [PubMed]
- Bae, Y.-J.; Yeon, J.-Y.; Sung, C.-J.; Kim, H.-S.; Sung, M.-K. Dietary Intake and Serum Levels of Iron in Relation to Oxidative Stress in Breast Cancer Patients. J. Clin. Biochem. Nutr. 2009, 45, 355–360. [Google Scholar] [CrossRef] [Green Version]
- Fonseca-Nunes, A.; Jakszyn, P.; Agudo, A. Iron and Cancer Risk—A Systematic Review and Meta-analysis of the Epidemiological Evidence. Cancer Epidemiol. Biomark. Prev. 2014, 23, 12–31. [Google Scholar] [CrossRef] [Green Version]
- Pinnix, Z.K.; Miller, L.D.; Wang, W.; D’Agostino, R., Jr.; Kute, T.; Willingham, C.; Hatcher, H.; Tesfay, L.; Sui, G.; Di, X.; et al. Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis. Sci. Transl. Med. 2010, 2, 43ra56. [Google Scholar] [CrossRef]
- Zhang, S.; Chen, Y.; Guo, W.; Yuan, L.; Zhang, D.; Xu, Y.; Nemeth, E.; Ganz, T.; Liu, S. Disordered hepcidin–ferroportin signaling promotes breast cancer growth. Cell. Signal. 2014, 26, 2539–2550. [Google Scholar] [CrossRef]
- Chang, V.C.; Cotterchio, M.; Khoo, E. Iron intake, body iron status, and risk of breast cancer: A systematic review and meta-analysis. BMC Cancer 2019, 19, 1–28. [Google Scholar] [CrossRef] [Green Version]
- Mustafa, R.M.A.; Husain, N.E.O.S.A. Changes in Serum Iron, Total Iron Binding Capacity and Transferrin Saturation Percent in Sudanese Females Newly Diagnosed with Breast Cancer at Khartoum Oncology Hospital: A case- control study. Sudan J. Med Sci. 2017, 12, 119–132. [Google Scholar] [CrossRef]
- Bajbouj, K.; Shafarin, J.; Abdalla, M.Y.; Ahmad, I.; Hamad, M. Estrogen-induced disruption of intracellular iron metabolism leads to oxidative stress, membrane damage, and cell cycle arrest in MCF-7 cells. Tumor Biol. 2017, 39, 1–12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cavalieri, E.; Chakravarti, D.; Guttenplan, J.; Hart, E.; Ingle, J.; Jankowiak, R.; Muti, P.; Rogan, E.; Russo, J.; Santen, R.; et al. Catechol estrogen quinones as initiators of breast and other human cancers: Implications for biomarkers of susceptibility and cancer prevention. Biochim. Biophys. Acta 2006, 1766, 63–78. [Google Scholar] [CrossRef] [PubMed]
- Jian, J.; Yang, Q.; Dai, J.; Eckard, J.; Axelrod, D.; Smith, J.; Huang, X. Effects of iron deficiency and iron overload on angiogenesis and oxidative stress—A potential dual role for iron in breast cancer. Free Radic. Biol. Med. 2011, 50, 841–847. [Google Scholar] [CrossRef] [Green Version]
- Kabat, G.C.; Rohan, T.E. Does excess iron play a role in breast carcinogenesis? An unresolved hypothesis. Cancer Causes Control 2007, 18, 1047–1053. [Google Scholar] [CrossRef]
- Huang, X. Does iron have a role in breast cancer? Lancet Oncol. 2008, 9, 803–807. [Google Scholar] [CrossRef] [Green Version]
- Cheng, M.; Liu, P.; Xu, L.X. Iron promotes breast cancer cell migration via IL-6/JAK2/STAT3 signaling pathways in a paracrine or autocrine IL-6-rich inflammatory environment. J. Inorg. Biochem. 2020, 210, 111159. [Google Scholar] [CrossRef]
- Claessens, A.K.M.; Ibragimova, K.I.E.; Geurts, S.M.E.; Bos, M.E.M.M.; Erdkamp, F.L.G.; Tjan-Heijnen, V.C.G. The role of chemotherapy in treatment of advanced breast cancer: An overview for clinical practice. Crit. Rev. Oncol./Hematol. 2020, 153, 102988. [Google Scholar] [CrossRef]
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
- Brody, J.G.; Moysich, K.B.; Humblet, O.; Attfield, K.R.; Beehler, G.P.; Rudel, R.A. Environmental pollutants and breast cancer: Epidemiologic studies. Cancer 2007, 109 (Suppl. S12), 2667–2711. [Google Scholar] [CrossRef]
- Momenimovahed, Z.; Salehiniya, H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer Targets Ther. 2019, 11, 151–164. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yazici, H.; Akin, B. Molecular Genetics of Metastatic Breast Cancer. Tumor Progress. Metastasis 2020, 1–18. [Google Scholar] [CrossRef] [Green Version]
- Tsang, J.Y.S.; Tse, G.M. Molecular Classification of Breast Cancer. Adv. Anat. Pathol. 2020, 27, 27–35. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.-M.; Oh, M.H.; Go, J.-H.; Han, K.; Choi, S.-Y. Molecular subtypes of triple-negative breast cancer: Understanding of subtype categories and clinical implication. Genes Genom. 2020, 42, 1381–1387. [Google Scholar] [CrossRef] [PubMed]
- Sørlie, T.; Perou, C.M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M.B.; Van De Rijn, M.; Jeffrey, S.S.; et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98, 10869–10874. [Google Scholar] [CrossRef] [Green Version]
- WHO. Cancer. 2022. Available online: https://www.who.int/news-room/fact-sheets/detail/cancer (accessed on 25 May 2022).
- Hu, K.; Ding, P.; Wu, Y.; Tian, W.; Pan, T.; Zhang, S. Global patterns and trends in the breast cancer incidence and mortality according to sociodemographic indices: An observational study based on the global burden of diseases. BMJ Open 2019, 9, e028461. [Google Scholar] [CrossRef]
- Gradishar, W.J.; Anderson, B.O.; Abraham, J.; Aft, R.; Agnese, D.; Allison, K.H.; Blair, S.L.; Burstein, H.J.; Dang, C.; Elias, A.D.; et al. NCCN Clinical Guidelines Breast Cancer (Version 5.2020): Invasive Breast Cancer; National Comprehensive Cancer: Network, PA, USA, 2020; p. 67. [Google Scholar]
- Collyar, D.E. Breast cancer: A global perspective. J. Clin. Oncol. 2001, 19 (Suppl. S18), 101s–105s. [Google Scholar]
- Binns, C.; Low, W.Y.; Lee, M.K. Breast cancer: An increasing public health problem in the Asia pacific region. Asia-Pac. J. Public Health 2013, 25, 364–367. [Google Scholar] [CrossRef] [Green Version]
- Islam, R.M.; Bell, R.J.; Billah, B.; Hossain, M.B.; Davis, S.R. Awareness of breast cancer and barriers to breast screening uptake in Bangladesh: A population based survey. Maturitas 2015, 84, 68–74. [Google Scholar] [CrossRef]
- Ahmed, S.; Sayeed, A.; Mallick, T.; Syfuddin, H.M. Knowledge and Practices on Breast Cancer among Bangladeshi Female University Students: A Cross-sectional Study. Asian Pac. J. Cancer Care 2020, 5, 19–25. [Google Scholar] [CrossRef]
- Burguin, A.; Diorio, C.; Durocher, F. Breast Cancer Treatments: Updates and New Challenges. J. Pers. Med. 2021, 11, 808. [Google Scholar] [CrossRef] [PubMed]
- Moo, T.-A.; Sanford, R.; Dang, C.; Morrow, M. Overview of Breast Cancer Therapy. PET Clin. 2018, 13, 339–354. [Google Scholar] [CrossRef] [PubMed]
- van Seijen, M.; Lips, E.H.; Thompson, A.M.; Nik-Zainal, S.; Futreal, A.; Hwang, E.S.; Verschuur, E.; Lane, J.; Jonkers, J.; Rea, D.W.; et al. Ductal carcinoma in situ: To treat or not to treat, that is the question. Br. J. Cancer 2019, 121, 285–292. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wen, H.Y.; Brogi, E. Lobular Carcinoma In Situ. Surg. Pathol. Clin. 2018, 11, 123–145. [Google Scholar] [CrossRef]
- Cooper, G.M. The Development and Causes of Cancer. In The Cell: A Molecular Approach, 2nd ed.; Sinauer Associates: Sunderland, MA, USA, 2000. Available online: https://www.ncbi.nlm.nih.gov/books/NBK9963/ (accessed on 22 May 2022).
- Masoud, V.; Pagès, G. Targeted therapies in breast cancer: New challenges to fight against resistance. World J. Clin. Oncol. 2017, 8, 120–134. [Google Scholar] [CrossRef] [Green Version]
- Ross, J.S.; Schenkein, D.P.; Pietrusko, R.; Rolfe, M.; Linette, G.P.; Stec, J.; Stagliano, N.E.; Ginsburg, G.S.; Symmans, W.F.; Pusztai, L.; et al. Targeted Therapies for Cancer 2004. Am. J. Clin. Pathol. 2004, 122, 598–609. [Google Scholar] [CrossRef]
- Maughan, K.L.; Lutterbie, M.A.; Ham, P.S. Treatment of breast cancer. Am. Fam. Physician 2010, 81, 1339–1346. [Google Scholar] [CrossRef]
- Mehata, A.K.; Bharti, S.; Singh, P.; Viswanadh, M.K.; Kumari, L.; Agrawal, P.; Singh, S.; Koch, B.; Muthu, M.S. Trastuzumab decorated TPGS-g-chitosan nanoparticles for targeted breast cancer therapy. Colloids Surf. B Biointerfaces 2018, 173, 366–377. [Google Scholar] [CrossRef]
- Tokumaru, Y.; Joyce, D.; Takabe, K. Current status and limitations of immunotherapy for breast cancer. Surgery 2019, 167, 628–630. [Google Scholar] [CrossRef]
- Bird, B.R.H.; Swain, S.M. Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems. Clin. Cancer Res. 2008, 14, 14–24. [Google Scholar] [CrossRef] [Green Version]
- Stebbing, J.; Copson, E.O.S. Herceptin (trastuzamab) in advanced breast cancer. Cancer Treat. Rev. 2000, 26, 287–290. [Google Scholar] [CrossRef] [PubMed]
- Curigliano, G.; Criscitiello, C. Successes and limitations of targeted cancer therapy in breast cancer. Prog. Tumor Res. 2014, 41, 15–35. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bedford, M.R.; Ford, S.J.; Horniblow, R.D.; Iqbal, T.H.; Tselepis, C. Iron Chelation in the Treatment of Cancer: A New Role for Deferasirox? J. Clin. Pharmacol. 2013, 53, 885–891. [Google Scholar] [CrossRef] [PubMed]
- Taniguchi, K.; Karin, M. NF-κB, inflammation, immunity and cancer: Coming of age. Nat. Rev. Immunol. 2018, 18, 309–324. [Google Scholar] [CrossRef] [PubMed]
- Alkhateeb, A.A.; Connor, J.R. The significance of ferritin in cancer: Anti-oxidation, inflammation and tumorigenesis. Biochim. Biophys. Acta 2013, 1836, 245–254. [Google Scholar] [CrossRef] [PubMed]
- Jiang, X.-P.; Elliott, R.L. Decreased Iron in Cancer Cells and Their Microenvironment Improves Cytolysis of Breast Cancer Cells by Natural Killer Cells. Anticancer Res. 2017, 37, 2297–2305. [Google Scholar] [CrossRef] [Green Version]
- Ford, S.; Obeidy, P.; Lovejoy, D.; Bedford, M.; Nichols, L.; Chadwick, C.; Tucker, O.; Lui, G.; Kalinowski, D.; Jansson, P.; et al. Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo. Br. J. Pharmacol. 2013, 168, 1316–1328. [Google Scholar] [CrossRef] [Green Version]
- Kontoghiorghe, C.N.; Kontoghiorghes, G.J. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Des. Dev. Ther. 2016, 10, 465–481. [Google Scholar] [CrossRef] [Green Version]
- Buss, J.L.; Greene, B.T.; Turner, J.; Torti, F.M.; Torti, S.V. Iron Chelators in Cancer Chemotherapy. Curr. Top. Med. Chem. 2004, 4, 1623–1635. [Google Scholar] [CrossRef]
- Coombs, R.P.M.; Grant, T.; Greenshields, A.L.; Arsenault, D.J.; Holbein, B.E.; Hoskin, D.W. Inhibitory effect of iron withdrawal by chelation on the growth of human and murine mammary carcinoma and fibrosarcoma cells. Exp. Mol. Pathol. 2015, 99, 262–270. [Google Scholar] [CrossRef]
- Jung, M.; Mertens, C.; Tomat, E.; Brüne, B. Iron as a Central Player and Promising Target in Cancer Progression. Int. J. Mol. Sci. 2019, 20, 273. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Greenshields, A.L.; Coombs, M.R.P.; Fernando, W.; Holbein, B.E.; Hoskin, D.W. DIBI, a novel 3-hydroxypyridin-4-one chelator iron-binding polymer, inhibits breast cancer cell growth and functions as a chemosensitizer by promoting S-phase DNA damage. BioMetals 2019, 32, 909–921. [Google Scholar] [CrossRef] [PubMed]
- Thompson, H.J.; Neil, E.S.; McGinley, J.N. Pre-Clinical Insights into the Iron and Breast Cancer Hypothesis. Biomedicines 2021, 9, 1652. [Google Scholar] [CrossRef]
- Goto, W.; Kashiwagi, S.; Asano, Y.; Takada, K.; Morisaki, T.; Takahashi, K.; Fujita, H.; Shibutani, M.; Amano, R.; Takashima, T.; et al. Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment. BMC Cancer 2020, 20, 1–10. [Google Scholar] [CrossRef]
- Tury, S.; Assayag, F.; Bonin, F.; Chateau-Joubert, S.; Servely, J.-L.; Vacher, S.; Becette, V.; Caly, M.; Rapinat, A.; Gentien, D.; et al. The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers. J. Pathol. 2018, 246, 103–114. [Google Scholar] [CrossRef] [PubMed]
- Bajbouj, K.; Shafarin, J.; Hamad, M. High-Dose Deferoxamine Treatment Disrupts Intracellular Iron Homeostasis, Reduces Growth, and Induces Apoptosis in Metastatic and Nonmetastatic Breast Cancer Cell Lines. Technol. Cancer Res. Treat. 2018, 17, 1–11. [Google Scholar] [CrossRef] [Green Version]
- Hoke, E.M.; Maylock, C.A.; Shacter, E. Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin. Free Radic. Biol. Med. 2005, 39, 403–411. [Google Scholar] [CrossRef]
- Lui, G.Y.L.; Obeidy, P.; Ford, S.J.; Tselepis, C.; Sharp, D.M.; Jansson, P.J.; Kalinowski, D.S.; Kovacevic, Z.; Lovejoy, D.B.; Richardson, D.R. The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity against Human Lung Tumor Xenografts and Molecular Mechanism of Action. Mol. Pharmacol. 2012, 83, 179–190. [Google Scholar] [CrossRef] [Green Version]
- Messa, E.; Cilloni, D.; Messa, F.; Arruga, F.; Roetto, A.; Saglio, G. Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary Myelofibrosis. Acta Haematol. 2008, 120, 70–74. [Google Scholar] [CrossRef]
- Chantrel-Groussard, K.; Gaboriau, F.; Pasdeloup, N.; Havouis, R.; Nick, H.; Pierre, J.-L.; Brissot, P.; Lescoat, G. The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox. Eur. J. Pharmacol. 2006, 541, 129–137. [Google Scholar] [CrossRef]
- Toyokuni, S. Role of iron in carcinogenesis: Cancer as a ferrotoxic disease. Cancer Sci. 2009, 100, 9–16. [Google Scholar] [CrossRef] [PubMed]
- Fukushima, T.; Kawabata, H.; Nakamura, T.; Iwao, H.; Nakajima, A.; Miki, M.; Sakai, T.; Sawaki, T.; Fujita, Y.; Tanaka, M.; et al. Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia. Anticancer Res. 2011, 31, 1741–1744. [Google Scholar] [PubMed]
- Messa, E.; Carturan, S.; Maffè, C.; Pautasso, M.; Bracco, E.; Roetto, A.; Messa, F.; Arruga, F.; Defilippi, I.; Rosso, V.; et al. Deferasirox is a powerful NF- B inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica 2010, 95, 1308–1316. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brown, R.A.M.; Richardson, K.L.; Kabir, T.D.; Trinder, D.; Ganss, R.; Leedman, P.J. Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology. Front. Oncol. 2020, 10, 476. [Google Scholar] [CrossRef]
- Dixon, S.J.; Stockwell, B.R. The Hallmarks of Ferroptosis. Annu. Rev. Cancer Biol. 2019, 3, 35–54. [Google Scholar] [CrossRef]
- Eckard, J.; Dai, J.; Wu, J.; Jian, J.; Yang, Q.; Chen, H.; Costa, M.; Frenkel, K.; Huang, X. Effects of cellular iron deficiency on the formation of vascular endothelial growth factor and angiogenesis. Iron deficiency and angiogenesis. Cancer Cell Int. 2010, 10, 28. [Google Scholar] [CrossRef] [Green Version]
- Prutki, M.; Poljak-Blazi, M.; Jakopovic, M.; Tomas, D.; Stipancic, I.; Zarkovic, N. Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. Cancer Lett. 2006, 238, 188–196. [Google Scholar] [CrossRef]
- Lane, D.J.R.; Merlot, A.M.; Huang, M.L.H.; Bae, D.H.; Jansson, P.J.; Sahni, S.; Kalinowski, D.S.; Richardson, D.R. Cellular iron uptake, trafficking and metabolism: Key molecules and mechanisms and their roles in disease. Biochim. Biophys. Acta 2015, 1853, 1130–1144. [Google Scholar] [CrossRef] [Green Version]
- Epis, M.R.; Giles, K.M.; Kalinowski, F.C.; Barker, A.; Cohen, R.J.; Leedman, P.J. Regulation of Expression of Deoxyhypusine Hydroxylase (DOHH), the Enzyme That Catalyzes the Activation of eIF5A, by miR-331-3p and miR-642-5p in Prostate Cancer Cells. J. Biol. Chem. 2012, 287, 35251–35259. [Google Scholar] [CrossRef] [Green Version]
- Puig, S.; Ramos-Alonso, L.; Romero, A.M.; Martínez-Pastor, M.T. The elemental role of iron in DNA synthesis and repair. Metallomics 2017, 9, 1483–1500. [Google Scholar] [CrossRef] [Green Version]
Cancer Stage | Stage 0 | Stage I & Stage II | Stage III | Stage IV | Reference(s) | |||
---|---|---|---|---|---|---|---|---|
Cancer Type | Lobular carcinoma (in situ). | Ductal carcinoma (in situ). | Early stage invasive carcinoma. | Locally advanced noninflammatory carcinoma. | Locally advanced inflammatory carcinoma. | Initial or recurrent metastatic condition. | [45] | |
Primary Therapy | NT or PT + TXF. | BCS&RT | BCS & RT. | Ind. Chemo. + BCS. & RT. | Ind. chemo. + mastecto my & RT. | RT. | [45,51] | |
Adjuvant Therapy | Negative hormone receptor | Chemotherapy. | Ind. chemo. & ET. | Chemotherapy. | [45] | |||
Positive hormone receptor | Chemotherapy & ET. | Ind. chemo. & ET. | ET+/chemotherapy. | [45,51] | ||||
ERBB2 Overexpression | Chemotherapy. &TRA (Herceptin). | Ind. Chemo. & TRA. | TRA+/chemotherapy. | [45,52] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Islam, S.; Hoque, N.; Nasrin, N.; Hossain, M.; Rizwan, F.; Biswas, K.; Asaduzzaman, M.; Rahman, S.; Hoskin, D.W.; Sultana, S.; et al. Iron Overload and Breast Cancer: Iron Chelation as a Potential Therapeutic Approach. Life 2022, 12, 963. https://doi.org/10.3390/life12070963
Islam S, Hoque N, Nasrin N, Hossain M, Rizwan F, Biswas K, Asaduzzaman M, Rahman S, Hoskin DW, Sultana S, et al. Iron Overload and Breast Cancer: Iron Chelation as a Potential Therapeutic Approach. Life. 2022; 12(7):963. https://doi.org/10.3390/life12070963
Chicago/Turabian StyleIslam, Sufia, Nazia Hoque, Nishat Nasrin, Mehnaz Hossain, Farhana Rizwan, Kushal Biswas, Muhammad Asaduzzaman, Sabera Rahman, David W. Hoskin, Saki Sultana, and et al. 2022. "Iron Overload and Breast Cancer: Iron Chelation as a Potential Therapeutic Approach" Life 12, no. 7: 963. https://doi.org/10.3390/life12070963